Karolinska Development's portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer
(Thomson Reuters ONE) -
STOCKHOLM 16 October 2017. Karolinska Development today announces that the
portfolio company Aprea Therapeutics AB has enrolled the first patient in a
Phase 1b/2 study with the drug candidate APR-246 for the treatment of esophageal
cancer.
Aprea develops novel anticancer compounds reactivating the tumour suppressor
protein, p53. This is the most frequently mutated gene in human cancer,
occurring in approximately 50% of all human tumours. p53-mutations are
associated with resistance to anticancer drugs and poor overall survival.
The clinical phase 1b/2 study will evaluate APR-246 in combination with
cisplatin and 5-fluorouracil for the treatment of platinum-resistant advanced
and metastatic esophageal cancer. The study is sponsored by the Peter MacCallum
Cancer Centre in Australia, and funded by the Victorian Government Department of
Health and Human Services through the Victorian Cancer Agency.
"The initiation of this phase 1b/2 study expands the potential use of APR-246 to
yet another indication area, which increases the value of the project and
reduces the risk. We will continue to follow Aprea's broad development program
with a keen interest", says Viktor Drvota, CEO, Karolinska Development.
APR-246 is since earlier being evaluated in a phase 2 study in patients with
platinum sensitive ovarian cancer. The results from this study are expected
during 2018. Moreover the drug candidate is being evaluated in clinical studies
in patients with platinum-resistant ovarian cancer and myelodysplastic syndrome.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota(at)karolinskadevelopment.com
Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange(at)karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a
proven track record as company builders and with access to a strong global
network.
For more information, please visit www.karolinskadevelopment.com
Aprea first Patient (ENG):
http://hugin.info/143071/R/2141903/820384.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 16.10.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 563723
Anzahl Zeichen: 4078
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 168 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development's portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
